Encouraging results from intracoronary infusion of Ad5FGF-4 in patients with stable angina
Study investigators was to verify whether administration of the gene encoding fibroblast growth factor (Ad5FGF-4) could improve myocardial perfusion compared to placebo.
A total of 52 patients with stable angina
And reversible ischemia involving 9% or more of the left ventricle on SPECT were randomized to gene therapy (n=35) or placebo (n=17).
After 8 weeks! 98% (n=51) of patients underwent a second SPECT scan.
The injection of Ad5FGF-4 produced a significant reduction in the size of the ischemic area (4.2% absolute! 21% relative; p<0.001) compared to no country wise email marketing list improvement among patients treated with placebo.
However! the change in perfusion defect size taiwan lists was not significant between patients treated with Ad5FGF-4 and those treated with placebo.
Ad5FGF-4 was well tolerated with no permanent adverse effects.
According to the authors! Therefore, intracoronary injection of Ad5FGF-4 showed a trend toward improved myocardial perfusion.
NEWSLETTER ON ANGINA PECTORIS AND ACUTE CORONARY SYNDROME
Xagena offers ongoing updates on Angina advice and development through Pectoris and Acute Coronary Syndrome.
You can subscribe to the newsletter by completing the form
Xagena Newsletter
and selecting “Angina” under Pathologies.
Only news of significant clinical or experimental Therefore, importance will be communicated.
Therefore! the newsletter will be sent monthly or bimonthly.
Plasma myeloperoxidase levels predict an increased risk of cardiovascular events in patients with acute coronary syndrome.